What predicts psychiatric symptoms over one year in methamphetamine-induced psychosis
Official title: Investigation of Factors Associated With Psychiatric Symptoms in Methamphetamine-Induced Psychotic Disorder: One-Year Longitudinal Study
Run by Elazığ Mental Health and Diseases Hospital · NCT07459257 · Data updated 2026-11-12
This will see if social, family, and individual factors predict changes in psychiatric symptoms over one year in adults with methamphetamine-induced psychosis.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 65 Years |
| Sex | Men only |
| Enrollment | 150 (estimated) |
| Sponsor | Elazığ Mental Health and Diseases Hospital Government |
| Locations | 1 site (Elâzığ, Elâzığ) |
| Status | Recruiting |
| Started | February 3, 2025 |
| Main results expected | July 28, 2025 |
| Study ends | December 31, 2026 |
| Registry record updated | September 10, 2026 |
| Trial ID | NCT07459257 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adult men aged 18 to under 65 with a DSM-5-TR diagnosis of methamphetamine-induced psychotic disorder who are medication-free for at least one month and able to give informed consent.
✕Probably not a fit
People with primary psychiatric diagnoses other than methamphetamine-induced psychosis, significant medical comorbidities listed in the exclusion criteria, alcohol use disorder, or who cannot attend monthly visits (including those outside the recruitment region) are unlikely to benefit from this protocol.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a one-year longitudinal observational follow-up of adult male patients diagnosed with methamphetamine-induced psychotic disorder who were medication-free for at least one month at entry. Participants were followed monthly with standardized psychometric instruments to record sociodemographic data, treatment adherence, perceived social support, insight, addiction-related clinical variables, and psychotic symptom severity. The study aimed to identify factors associated with relapse-remission patterns and symptom trajectory over time. It was conducted at Elazığ Mental Health and Diseases Hospital using prospective data collection and repeated measures analyses.
Why it matters
Potential benefit: If successful, the findings could help clinicians anticipate relapse and personalize social and treatment supports to reduce symptom persistence.
How similar studies have gone: Most prior work has been cross-sectional or retrospective, so longitudinal prediction of symptom trajectories in this population is limited and this approach is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
* Methamphetamine-Induced Psychotic Disorder (MP) Group:
\*Inclusion Criteria:
* Diagnosis of MP according to DSM-5-TR
* Medication-free for at least one month prior to admission
* Age ≥ 18 years and \<65 years
* Provided informed consent
* Methamphetamine-Induced Psychotic Disorder (MP) Group:
* Exclusion Criteria:
* Hypertension
* Diabetes mellitus
* Chronic kidney disease
* Rheumatoid arthritis
* Systemic lupus erythematosus
* Cardiac illness
* Severe neurological disorders
* Immunological or systemic illness
* Primary psychiatric disorders other than MP
* Alcohol use disorder
Where it's running
-
Elazığ Mental Health and Diseases Hospital
Elâzığ, Elâzığ, Turkey (Türkiye) Recruiting
Study contacts
- Study coordinator: Mehmet Hamdi ÖRÜM, MD, Assoc. Prof., Psychiatrist
- Email: mhorum@hotmail.com
- Phone: +905382207558
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Psychiatric Symptoms in Methamphetamine Psychosis With or Without Lifetime Cannabis Use
This study tests whether lifetime cannabis use changes the course and severity of psychiatric symptoms in people hospitalized with methamphetamine-induced psychosis.
-
ECG changes in adults using methamphetamine with and without psychosis
This project will see if heart ECG measurements differ between adults hospitalized for methamphetamine use who have psychosis and those who do not.
-
Type D Personality and Life Satisfaction in Bipolar II and Major Depressive Disorder
This study tests how Type D personality relates to life satisfaction in adults with Bipolar II or Major Depressive Disorder and in healthy controls.
-
Cognitive Disengagement Syndrome in Functional Neurological Symptom Disorder
This study tests whether adults with Functional Neurological Symptom Disorder have more sluggish cognitive tempo symptoms than healthy people.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.